PATHWAYS TO CARE FOR ADULTS WITH COVID-19





Local adaptation may be necessary as assessment of overall risk and appropriate models of care may vary across jurisdictions

VERSION 4.4

PUBLISHED 27 OCTOBER 2022

ADULT WITH CONFIRMED OR PRESUMED COVID-19 Asymptomatic or Symptoms or signs of MODERATE disease Symptoms or signs symptoms and signs of SEVERE disease **CLINICAL PRESENTATION** of MILD disease An individual with no clinical features A stable patient with evidence of A patient with signs of moderate suggestive of moderate or more lower respiratory tract disease: disease who is deteriorating severe disease: • during clinical assessment, such as • no OR mild symptoms and signs A patient meeting any of the - oxygen saturation 92-94% on following criteria: (fever, cough, sore throat, malaise, room air at rest headache, muscle pain, nausea, respiratory rate ≥30 breaths/min desaturation or breathlessness vomiting, diarrhoea, loss of taste oxygen saturation <92% on room with mild exertion and smell) air at rest or requiring oxygen or on imaging no new shortness of breath or • lung infiltrates >50%. difficulty breathing on exertion no evidence of lower respiratory tract disease during clinical assessment or on imaging (if performed) **Assess Risk Assess Risk ANY RISK FACTORS FOR ANY RISK FACTORS FOR POOR OUTCOMES POOR OUTCOMES** Older age, e.g. over 50 years • Older age, e.g. over 50 years for Aboriginal and Torres Strait for Aboriginal and Torres Strait Islander people, or otherwise over Islander people, or otherwise over 65 years. 65 years. No vaccine dose or SARS-CoV-2 No vaccine dose or SARS-CoV-2 S infection in the last ~3-6 month infection in the last ~3-6 months RISK OF POOR OUTCOM Pregnant Pregnant Comorbidities: Comorbidities: - respiratory compromise, - respiratory compromise, including COPD, asthma and including COPD, asthma and bronchiectasis bronchiectasis - cardiovascular disease, including cardiovascular disease, including hypertension hypertension - obesity (BMI >30 kg/m²) - obesity (BMI >30 kg/m²) - diabetes - diabetes - renal failure - renal failure - immunocompromising conditions - immunocompromising conditions (* see below) (* see below) Geographical remoteness and Geographical remoteness and lack of access to higher level lack of access to higher level healthcare healthcare Concerns about personal safety or Concerns about personal safety or lack of access to care at home lack of access to care at home YES NO YES NO **LOW RISK VERY HIGH RISK MEDIUM RISK HIGH RISK IMMEDIATE CARE AT HOME CARE AT HOME CONSIDER AMBULANCE WITH STANDARD** WITH INCREASED TRANSFER TO **TRANSFER TO** LEVEL OF SUPPORT LEVEL OF SUPPORT HOSPITAL **HOSPITAL WITH ICU** Refer to Depending on severity, Goals of care refer to MANAGEMENT OF The decision to transfer to hospital should be made after consideration of goals of care. MANAGEMENT of **ADULTS WITH MILD** SUPPORTIVE CARE **ADULTS WITH MILD COVID-19 flowchart COVID-19** flowchart MANAGEMENT **OF ADULTS WITH MODERATE TO SEVERE COVID-19** flowchart Consider eligibility for drug treatments

• Drug treatments for adults with COVID-19

• Drug treatments for pregnant or breastfeeding women with COVID-19 Refer to the decision support tool for specific guidance on drug treatments for at

Refer to the current summaries of drug treatments for COVID-19:

risk adults with COVID-19 who do not require oxygen.

*IMMUNOCOMPROMISING CONDITIONS:

- Primary or acquired immunodeficiency:
- Haematologic neoplasms: leukaemias, lymphomas, myelodysplastic syndromes
- Post-transplant: solid organ (on immunosuppressive therapy), haematopoietic stem cell transplant (within 24 months)
- Immunocompromised due to primary or acquired (AIDS) immunodeficiency or Down syndrome
- Immunosuppressive therapy (current or recent)
- Chemotherapy, whole body radiotherapy or total lymphoid irradiation
- High-dose corticosteroids (≥20 mg of prednisone per day, or equivalent) for ≥14 days - Selected other potent immunosuppressive therapies (refer to ATAGI advice)

Source

National Clinical Evidence Taskforce - Australian guidelines for the clinical care of people with COVID-19.